MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Botulinum Neurotoxin (BoNT) treatment in functional movement disorders: an extended follow up

J. Dijk, M. Tijssen, J. Koelman, Y. Dreissen, F. Lambert (Groningen, Netherlands)

Meeting: 2019 International Congress

Abstract Number: 396

Keywords: Botulinum toxin: Clinical applications: other, Psychogenic movement disorders(PMD): Treatment

Session Information

Date: Monday, September 23, 2019

Session Title: Functional (Psychogenic) Movement Disorders

Session Time: 1:45pm-3:15pm

Location: Les Muses Terrace, Level 3

Objective: To assess the long term effect of treatment with botulinum neurotoxin (BoNT) in patients with functional jerky or tremorous movement disorders.

Background: Treatment options for functional movement disorders are scarce and not studied extensively. We previously studied the effects of botulinum toxin (BoNT) treatment in a randomized double-blinded clinical trial. 81% of patients improved after 1 year follow-up but there was no significant difference between treatment with BoNT and placebo after 4 months and follow-up. In the current study we aimed to assess the long-term effects of BoNT in functional movement disorders.

Method: An extended follow up study of the BoNT trial was performed, in which 48 patients were approached 3 to 7 years after start of the study. We assessed symptom severity, using the self-reported Clinical Global Impression-Severity (CGI-S) and the Clinical Global Impression-Improvement scale (CGI-I). Physical functioning, work status, psychiatric symptoms, additional treatments and development of other functional neurological symptoms were also studied.

Results: The 46 patients who actively participated in the trial were included in this study. Ten still received BoNT injections, as they experienced an increase of symptoms when the effect of BoNT was supposed to wear off after three months. Of the 36 patients who stopped BoNT treatment after the trial, 21 (61%) patients experienced no change or improvement of motor symptoms since the end of the BoNT trial according to the CGI-I. Most (20 patients) had improved during the original trial. No change was found in motor severity scores since the end of the BoNT trial (p=0,690). Disease burden, anxiety and physical functioning had not improved compared to the start of the original study. The mean of the depression scores had not changed, but it did show a significant difference (p=0,024).

Conclusion: Even after treatment cessation a large proportion of patients improved or retained the improvement in motor symptoms. The effect of treatment-intervention in functional movement disorders appears to create a long-lasting effect of motor symptoms; however this did not translate into improvement of disease burden, disability and quality of life.

To cite this abstract in AMA style:

J. Dijk, M. Tijssen, J. Koelman, Y. Dreissen, F. Lambert. Botulinum Neurotoxin (BoNT) treatment in functional movement disorders: an extended follow up [abstract]. Mov Disord. 2019; 34 (suppl 2). https://www.mdsabstracts.org/abstract/botulinum-neurotoxin-bont-treatment-in-functional-movement-disorders-an-extended-follow-up/. Accessed June 14, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/botulinum-neurotoxin-bont-treatment-in-functional-movement-disorders-an-extended-follow-up/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Humor processing is affected by Parkinson’s disease and levodopa
      • Help & Support
      • About Us
      • Cookies & Privacy
      • Wiley Job Network
      • Terms & Conditions
      • Advertisers & Agents
      Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
      Wiley